Advanced searches left 3/3

Aspergillosis - U.S. Department of Veterans Affairs

Summarized by Plex Scholar
Last Updated: 06 February 2022

* If you want to update the article please login/register

Efficacy of Rezafungin in Prophylactic Mouse Models of Invasive Candidiasis, Aspergillosis, and Pneumocystis Pneumonia.

Antifungal prophylaxis has been used to reduce infectious fungal disease caused by Candida spp. , Aspergillus spp. , and Pneumocystis jirovecii in patients at risk of opportunistic infections such as allogeneic blood or marrow transplant recipients, patients of hematologic disease treated by chemotherapy, patients on immunosuppressive therapy, or patients on immunosuppressive therapy. Candida CFU burden reduction was generally higher with rising drug levels, and when rezafungin was administered closer to the time of fungal challenge. In comparison to Pneumocystis murina, rezafungin reduced trophic nuclei and asci counts at all doses tested. Both higher doses compared to vehicle prevented disease and had similar effect to the active control trimethoxazole at human equivalent doses for prevention. These results support phase 3 of rezafungin's manufacturing and the possibility of single-agent prophylaxis against invasive fungal disease caused by Candida spp. , Aspergillus spp. , and Pneumocystis jirovecii.

Source link: https://doi.org/10.1128/AAC.01992-20

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions